HOOK HOOKIPA Pharma Inc.

Biotech Analyst Ratings

Latest News

1. 16 May 2022 HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights

   • HB-200 program on track to report Phase 1 data mid-year, Phase 2 data in combination with pembrolizumab in second half of 2022
     
   • Q1 capital raise and Gilead collaboration funding generated a strong cash position of $142 million

   NEW YORK and VIENNA, Austria, May 16, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2022.

   "We observed strong external validation of our novel arenaviral platform in the first quarter with our collaboration agreement with Gilead and our capital raise, which drew funding from new and existing top-tier investors…

   View Full Article
2. 09 May 2022 HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022

   NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022.
   

   The Company will not be conducting a conference call in conjunction with this earnings release.
   
   About HOOKIPA

   HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA's replicating and non-replicating…

   View Full Article
3. 03 May 2022 HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

   NEW YORK and VIENNA, Austria, May 03, 2022 (GLOBE NEWSWIRE) -- New York, US and Vienna, Austria, May 2, 2022 - HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate in and present at the following upcoming investor conferences:
   

   • BofA Securities 2022 Healthcare Conference, May 10-13, Las Vegas 
     Fireside Chat: May 10, 8:40am PT

   • 2022 RBC Capital Markets Global Healthcare Conference, May 17-18, New York
     Fireside Chat: May 17, 4:05pm ET
     

   • H.C. Wainwright Global Investment Conference, May 23-26, Miami Beach
     Fireside Chat: May 24, 2:00pm ET
     

   Webcasts will be available within the Investors & Media…

   View Full Article
4. 02 May 2022 HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer

   NEW YORK and VIENNA, Austria, May 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately. Christine joined HOOKIPA in August 2019 as Chief Business Officer and has played a critical role in securing several strategic business collaborations for HOOKIPA's novel arenaviral immunotherapeutics that help position the science and the company for continued growth.
   

   "Since day one, Christine has applied her deep experience in business development and commercial planning to help uncover, negotiate and secure significant collaborations…

   View Full Article
5. 20 April 2022 HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors

   NEW YORK and VIENNA, Austria, April 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Tim Reilly, Ph.D. to its Board of Directors, effective immediately.
   

   "We're pleased to have Tim join our Board as we advance our oncology pipeline of novel arenaviral immunotherapeutics in and towards the clinic," said Joern Aldag, Chief Executive Officer at HOOKIPA. "Tim's experience in product development, especially driving early clinical development that supports eventual marketed products, is enormously relevant to our current focus. We will benefit from his insights on our ongoing Phase 2…

   View Full Article